Theranostic advances in vascular malformations
(2020) The Journal of Investigative Dermatology — Vol. 140, n° 4, p. 756 (2020)
Files
DekeuleneeretalJID2020.pdf
Open Access - Adobe PDF
- 933.96 KB
Details
- Authors
- Abstract
- Vascular malformations are subdivided into capillary, lymphatic, venous, arteriovenous, and mixed malfor- mations, according to the type of affected vessels. Until a few years ago, treatment options were limited to sclerotherapy and/or surgery. Since, it has been demonstrated that the majority of vascular malfor- mations are caused by inherited or somatic mutations in various genes. These mutations lead to hyperac- tivity of two major signaling pathways: the RAS/ mitogen-activated protein kinase and the phosphati- dylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathways. These discoveries paved the way for the development and testing of targeted molecular inhibitors as therapies for vascular anomalies via repurposing of anticancer drugs.
- Affiliations
Citations
Dekeuleneer, V., Seront, E., Van Damme, A., Boon, L., & Vikkula, M. (2020). Theranostic advances in vascular malformations. The Journal of Investigative Dermatology, 140(4), 756. https://doi.org/10.1016/j.jid.2019.10.001 (Original work published 2020)